Clinical Research in Radiation Oncology: Current Status and Future Directions

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Oncology".

Deadline for manuscript submissions: 15 October 2025 | Viewed by 1223

Special Issue Editor


E-Mail Website
Guest Editor
Radiation Oncology Department, ASST Spedali Civili and University of Brescia, 25123 Brescia, Italy
Interests: radiotherapy; cancer therapy; radiation therapy; radiology; lung cancer

Special Issue Information

Dear Colleagues,

Radiotherapy is a powerful weapon against cancer, alone or in combination with surgery or medical treatments. Much progress has been made in recent years, and new technologies have been shown to significantly increase the benefit/harm ratio, resulting in greater local control and limited toxicities. Despite this, many questions regarding the appropriateness of modern radiotherapy, the clinical management of patients, and biological issues still remain unanswered. This Special Issue of the Journal of Clinical Medicine, entitled "Clinical Research in Radiation Oncology: Current Status and Future Directions", aims to provide an opportunity for radiation oncologists and the entire oncology community to discuss current issues in radiotherapy and present original data, literature reviews, and consensuses that reflect research and clinical interests in radiotherapy.

Dr. Paolo Borghetti
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • radiation oncology
  • radiobiology
  • stereotactic body radiotherapy
  • multidisciplinary team
  • integrated treatment
  • predictive and prognostic biomarkers
  • cancer treatment

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

11 pages, 567 KiB  
Article
Plan Quality Comparison at Five Years in Two Cohorts of Breast Cancer Patients Treated with Helical Tomotherapy
by Samantha Dicuonzo, Maria Alessia Zerella, Mattia Zaffaroni, Maria Giulia Vincini, Karl Amin, Giuseppe Ronci, Micol D’arcangelo, Damaris Patricia Rojas, Anna Morra, Marianna Alessandra Gerardi, Cristiana Fodor, Raffaella Cambria, Rosa Luraschi, Federica Cattani, Paolo Veronesi, Francesca De Lorenzi, Mario Rietjens, Roberto Orecchia, Maria Cristina Leonardi and Barbara Alicja Jereczek-Fossa
J. Clin. Med. 2025, 14(5), 1630; https://doi.org/10.3390/jcm14051630 - 27 Feb 2025
Viewed by 943
Abstract
Objectives: this study aimed to evaluate the evolution of planned dose distribution quality in two groups of breast cancer patients treated with hypofractionated intensity-modulated radiotherapy (IMRT) using Helical TomoTherapy® at our institute 5 years apart. Methods: the analysis included two cohorts [...] Read more.
Objectives: this study aimed to evaluate the evolution of planned dose distribution quality in two groups of breast cancer patients treated with hypofractionated intensity-modulated radiotherapy (IMRT) using Helical TomoTherapy® at our institute 5 years apart. Methods: the analysis included two cohorts of patients who underwent implant-based immediate breast reconstruction (IBR) and received post-mastectomy IMRT to the chest wall and infra/supraclavicular lymph nodes, following a 15-fraction regimen (2.67 Gy per fraction). The first group was treated between 2012 and 2015, while the second received treatment between 2019 and 2020. Dosimetric indices derived from dose–volume histograms used in clinical practice were analyzed to assess dose distribution quality. A quantitative scoring system was applied retrospectively to compare the two groups in terms of target coverage and organ-at-risk (OAR) sparing. Additionally, capsular contracture (CC) incidence was examined in both cohorts. Results: A total of 240 patients were included in the study. The percentage of optimal treatment plans increased from 70.8% in the 2012–2015 cohort to 77.5% in the 2019–2020 cohort, while compromised plans decreased from 10.8% to 7.5%. Furthermore, the incidence of moderate-to-severe CC dropped from 54.8% in the earlier cohort to 43.5% in the later one. Conclusions: Helical Tomotherapy® has demonstrated the ability to achieve a high rate of optimal treatment plans concerning both PTV coverage and OAR sparing in a challenging population of postmastectomy patients with IBR. The learning curve showed that, after 5 years, the rate of optimal plans was increased, accompanied by a reduction in compromised plans and treatment-related toxicity. Full article
Show Figures

Figure 1

Back to TopTop